Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic data suggest...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, Keiji, James-Bott, Anna, Tye, Mark A., Yamamoto, Leona, Samur, Mehmet K., Tai, Yu-Tzu, Dunford, James, Johansson, Catrine, Senbabaoglu, Filiz, Philpott, Martin, Palmer, Charlotte, Ramasamy, Karthik, Gooding, Sarah, Smilova, Mihaela, Gaeta, Giorgia, Guo, Manman, Christianson, John C., Payne, N. Connor, Singh, Kritika, Karagoz, Kubra, Stokes, Matthew E., Ortiz, Maria, Hagner, Patrick, Thakurta, Anjan, Cribbs, Adam, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth C., Oppermann, Udo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834298/
https://www.ncbi.nlm.nih.gov/pubmed/36631435
http://dx.doi.org/10.1038/s41408-023-00787-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834298/
https://www.ncbi.nlm.nih.gov/pubmed/36631435
http://dx.doi.org/10.1038/s41408-023-00787-w

Ejemplares similares